• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Dupilumab-induced peripheral neuropathy in a patient with severe asthma
The anti –interleukin (IL)-4 receptor, an antibody dupilumab is used in the treatment of severe asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Common adverse events reportedly include injection site reactions, conjunctivitis, headache, and oral herpes. Dr Lee et al1 provided the f irst reported case of very severe chronic inflammatory demyelinating polyradiculoneuropathy that developed 1.5 years after the initiation of dupilumab treatment for atopic dermatitis. Similarly, we have encountered a case of peripheral neuropathy in a patient with severe asthma being treated with du pilumab and wish to...
Source: Annals of Allergy, Asthma and Immunology - April 28, 2022 Category: Allergy & Immunology Authors: Mayuka Yamane, Hiroshi Ohnishi, Kimiko Tsuji, Kazuki Anabuki, Akihito Yokoyama Tags: Correspondence Source Type: research

M002 new-onset rosacea in a patient on dupilumab treatment for nasal polyposis
Dupilumab is a humanized monoclonal antibody that inhibits the interleukin-4 receptor (IL-4R α), thereby blocking IL-4 and IL-13 signaling of the Th2 pathway. Via Th2 blockade, Dupilumab decreases eosinophil recruitment, rendering it an effective treatment for nasal polyps caused by chronic accumulation of eosinophils in the paranasal sinus mucosa. Side effects reported during clinical tri als included conjunctivitis, injection site reactions, and herpes infections.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2021 Category: Allergy & Immunology Authors: J. Fortier, J. Justice, A. Debenedetto, L. Cuervo-Pardo Source Type: research